Stock listing
A4046T Stock Price, News, Filings & Events — Outlook Therapeutics, Inc.
Selected listing: A4046T · LSX · EUR · DE
This page tracks Outlook Therapeutics, Inc.'s A4046T:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A4046T:LSX. A4046T:LSX is the stock-level entry point for investors researching Outlook Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A4046T:LSX
- Asset type
- Stock
- Market cap
- $157.0M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LSX
- Currency
- EUR
Outlook Therapeutics, Inc. A4046T:LSX stock context
This page tracks Outlook Therapeutics, Inc.'s A4046T:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A4046T:LSX. A4046T:LSX is the stock-level entry point for investors researching Outlook Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Outlook Therapeutics, Inc.
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
August 27, 2026
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
August 12, 2026
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
July 24, 2026
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA as a Treatment for Wet AMD
June 17, 2026
Outlook Therapeutics, Inc. earnings calls
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call
August 14, 2026 · Replay with transcript and chapters
Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call
August 14, 2024 · Replay with transcript and chapters
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call
May 16, 2024 · Replay with transcript and chapters
Research Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for A4046T:LSX.
Outlook Therapeutics, Inc. company profile
View the public company page for Outlook Therapeutics, Inc. on 6ix.
Outlook Therapeutics, Inc. news
Read company news and market updates connected to Outlook Therapeutics, Inc..
Outlook Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Outlook Therapeutics, Inc..
Alternate listings
OTLK:NASDAQ
US · USD
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.
41O:GETTEX
DE · EUR
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.
OTLK:BOATS
US · USD
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.
A4046T:LS
DE · EUR
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.
41O:TRADEGATE
DE · EUR
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.
41O:FWB
DE · EUR
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.
41O:DUS
DE · EUR
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.
41O:HAM
DE · EUR
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.
41O:MUN
DE · EUR
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.
41O:SWB
DE · EUR
Alternate listing for Outlook Therapeutics, Inc.; the primary context on this page is A4046T:LSX.